Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Melanoma
Age: Between 18 Year(s) - 100 Year(s)
Gender: Male or Female

Other Inclusion Criteria:

1) Has histologically or cytologically confirmed melanoma. 2) Has clinically detectable and resectable Stage IIIB or IIIC or IIID melanoma amenable to surgery. 3) Has provided a baseline tumor biopsy.

You may not be eligible for this study if the following are true:

1) Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within 7 days before the first dose of study intervention. 2) Has a known additional malignancy that is progressing or requires active treatment within the past 2 years. 3) Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies